NasdaqGM:APGEBiotechs
How Investors Are Reacting To Apogee Therapeutics (APGE) Asthma Data and 2026 Immunology Pipeline Ambitions
Earlier in January 2026, Apogee Therapeutics reported positive interim Phase 1b data for its half-life extended anti-IL-13 antibody zumilokibart (APG777) in mild-to-moderate asthma, showing a favorable safety profile and strong, durable FeNO suppression after a single 720 mg dose.
The update also outlined an ambitious 2026 clinical roadmap for zumilokibart and combination asset APG279 across atopic dermatitis and broader immunology indications, underscoring Apogee’s push to build a...